Niagen Bioscience Shares Surge 18% After Reporting Record 2025 Results

The biotech company maintained a cautious outlook for 2026 amid M&A considerations.

Published on Mar. 5, 2026

Got story updates? Submit your updates here. ›

Niagen Bioscience Inc., a Los Angeles-based biotechnology company, saw its shares jump 18.41% in after-hours trading on Wednesday after reporting its strongest annual performance so far. In 2025, the company's full-year net sales increased 30% year over year to $129.4 million, reaching the upper end of its forecast, while net income rose to $17.7 million, roughly double the $8.6 million reported the previous year.

Why it matters

Niagen Bioscience's record financial results and strong cash position of $64.8 million with zero debt have positioned the company to potentially pursue strategic acquisitions, as indicated by CEO Rob Fried. However, the company maintained a conservative outlook for 2026, projecting 15% revenue growth, which could signal caution amid broader economic uncertainties.

The details

Niagen Bioscience, which produces NAD+ supplements, closed the regular trading session on Wednesday up 1.44% at $4.94 per share. The after-hours rally came after the company reported its 2025 financial results, which included a 30% year-over-year increase in net sales to $129.4 million and a doubling of net income to $17.7 million. The company's CEO, Rob Fried, told Benzinga that Niagen Bioscience is actively evaluating acquisition targets, though no deals have been finalized yet. For 2026, the company projected revenue of $145 million, representing approximately 15% growth, which Fried described as a 'fairly conservative' outlook.

  • Niagen Bioscience reported its 2025 financial results on Wednesday, March 5, 2026.
  • In 2025, Niagen Bioscience's net sales increased 30% year over year to $129.4 million.

The players

Niagen Bioscience Inc.

A Los Angeles-based biotechnology company that produces NAD+ supplements.

Rob Fried

The CEO of Niagen Bioscience Inc.

Got photos? Submit your photos here. ›

What they’re saying

“We are looking at companies. We have not found one to pull the trigger on yet, but it is possible.”

— Rob Fried, CEO (Benzinga)

“Historically, we tend to be fairly conservative with our projections.”

— Rob Fried, CEO (Benzinga)

What’s next

The company's potential acquisition plans and its ability to execute on its conservative 2026 revenue forecast will be closely watched by investors in the coming months.

The takeaway

Niagen Bioscience's strong financial performance and healthy cash position have positioned the company to potentially pursue strategic acquisitions, though it is maintaining a cautious outlook for 2026 amid broader economic uncertainties. The company's ability to navigate these challenges and capitalize on its growth opportunities will be key to its future success.